Ticker League

Stock-Based Compensation for Alnylam Pharmaceuticals (ALNY)

As of · Reported

Metric

Latest period

$361.68M

YoY change

+28.0%

5Y CAGR

+20.0%

Peak year (2025)

$348.24M

Stock-Based Compensation history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025

Latest: $348.24M

Stock-Based Compensation growth chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025

Latest: +28.0%

Stock-Based Compensation history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025

  • 2025$348.24M+28.0%
  • 2024$272.08M+22.7%
  • 2023$221.68M-3.9%
  • 2022$230.65M+39.2%
  • 2021$165.72M+18.5%
  • 2020$139.87M-20.0%
  • 2019$174.84M+10.8%
  • 2018$157.75M+70.0%
  • 2017$92.82M+22.9%
  • 2016$75.53M+65.0%
  • 2015$45.78M+38.5%
  • 2014$33.06M+59.7%
  • 2013$20.70M+67.5%
  • 2012$12.36M-26.4%
  • 2011$16.80M-13.1%
  • 2010$19.34M-4.1%
  • 2009$20.17M+11.9%
  • 2008$18.03M+24.6%
  • 2007$14.47M+74.3%
  • 2006$8.30M—
  • 2005$0.00-100.0%
  • 2004$4.11M—
  • 2003$0.00—
  • 2002$0.00—

Stock-Based Compensation values are taken from Alnylam Pharmaceuticals's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About Stock-Based Compensation at Alnylam Pharmaceuticals (ALNY)

Stock-Based Compensation for Alnylam Pharmaceuticals (ALNY): headline value $361.68M · YoY +28.0%. Annual and quarterly series, chart, and tables are below.

Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .

The 2025 reading of Alnylam Pharmaceuticals (ALNY) stock-based compensation is $348.24M – grew 28.0% year-over-year.

Alnylam Pharmaceuticals stock-based compensation compound annual growth for the 2020–2025 (5 years) window is +20.0%, with mixed annual results across the window.

$348.24M stands as the all-time-high annual stock-based compensation, posted in 2025, against a low of $0.00 during 2002.

Alnylam Pharmaceuticals Stock-Based Compensation by Year

Alnylam Pharmaceuticals Stock-Based Compensation 2025: $348.24M

Alnylam Pharmaceuticals posted stock-based compensation of $348.24M in 2025, grew 28.0% from 2024. This figure represents the highest annual value in the available history.

Alnylam Pharmaceuticals Stock-Based Compensation 2024: $272.08M

In 2024, Alnylam Pharmaceuticals reported stock-based compensation of $272.08M, grew 22.7% from 2023.

Alnylam Pharmaceuticals Stock-Based Compensation 2023: $221.68M

Alnylam Pharmaceuticals stock-based compensation in 2023 was $221.68M, edged down 3.9% below 2022.

Alnylam Pharmaceuticals Stock-Based Compensation 2022: $230.65M

2022's stock-based compensation for Alnylam Pharmaceuticals came in at $230.65M, surged 39.2% from 2021.

Alnylam Pharmaceuticals Stock-Based Compensation 2021: $165.72M

Alnylam Pharmaceuticals stock-based compensation in 2021 was $165.72M.

See more financial history for Alnylam Pharmaceuticals (ALNY).

Sector peers by Stock-Based Compensation

Healthcare peers of Alnylam Pharmaceuticals (ALNY), ranked by their latest stock-based compensation

Frequently asked questions

Alnylam Pharmaceuticals (ALNY) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Capital Return